Stockreport

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]

Structure Therapeutics Inc. - American Depositary Shares  (GPCR) 
PDF developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinica [Read more]